News

Filter

Current filters:

Immunosuppressants

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

08-09-2014

UK pharma major GlaxoSmithKline has reported positive data from its Phase III asthma studies of mepolizumab,…

GlaxoSmithKlineGSKImmunosuppressantsmepolizumabMepolizumabPharmaceuticalResearchRespiratory and PulmonaryUK

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

11-08-2014

The Scottish Medicines Consortium has approved the prescribing on the National Health Service of Roche’s…

Anti-Arthritics/RheumaticsImmunologyImmunosuppressantsNHSPharmaceuticalRegulationRoActemraRocheTocilizumabUK

MS market to reach $20 billion in 2023 boosted by five new therapies

MS market to reach $20 billion in 2023 boosted by five new therapies

08-08-2014

The forecast launch of five immunomodulatory therapies for relapsing forms of multiple sclerosis will…

CNS DiseasesEuropeImmunosuppressantsJapanMarkets & MarketingMSPharmaceuticalUSA

NICE consulting again on Celgene's Revlimid for multiple myeloma

NICE consulting again on Celgene's Revlimid for multiple myeloma

31-07-2014

The UK clinical guidance body, the National Institute for Health and Care Excellence (NICE), is again…

Celgene Corp.ImmunosuppressantslenalidomideOncologyPharmaceuticalRegulationRevlimidUK

Back to top